Drug Treatments for Osteoporosis — A Consultant’s Guide
At the London Osteoporosis Clinic, pharmacological treatment is always part of a broader clinical strategy — not the entirety of it. Drug therapy is prescribed only when a patient’s clinical assessment, bone density results, and fracture risk profile indicate that it is warranted, and it is always accompanied by appropriate nutritional and exercise support.
The guide below summarises the principal drug treatments used in osteoporosis management, how each works, and the patient profile for which it is most appropriate. It is intended to support informed conversations with your consultant — not to replace clinical guidance.
Schematic illustration of the effect of an anabolic or a bone-building agent, followed by an antiresorptive on spine BMD (a) and on vertebral fracture incidence in postmenopausal women with high fracture risk, defined by previous vertebral fracture and low BMD (b).
Understanding the Biology of Teriparatide vs PTH
This chart illustrates the biological differences between Teriparatide (a synthetic form of the first 34 amino acids of parathyroid hormone) and PTH, the body’s natural 84–amino acid hormone.
Teriparatide, given through daily injections, works by intermittently stimulating PTH receptors to promote new bone formation — making it an anabolic therapy ideal for osteoporosis treatment.
In contrast, continuous high levels of natural PTH lead to bone resorption (a catabolic effect), regulating calcium balance but potentially causing bone loss if sustained.
Our clinicians integrate these biological principles to optimise bone strength, reduce fracture risk, and maintain calcium homeostasis as part of a holistic, personalised care plan.
Antiresorptive Agents
Antiresorptive drugs slow or stop bone loss by inhibiting the activity of osteoclasts — the cells that break down old bone. They stabilise bone density and reduce fracture risk but do not directly stimulate new bone formation. They are the most widely prescribed first-line pharmacological treatment for osteoporosis.
Bisphosphonates
UK brand name: Alendronic acid (Binosto, Fosamax); Risedronate (Actonel); Ibandronate (Bonviva); Zoledronic acid (Aclasta)
Class: Antiresorptive
How it works: Bisphosphonates bind to bone mineral and inhibit osteoclast-mediated resorption, reducing the rate at which bone is broken down. They are effective at both spine and hip sites and reduce vertebral, non-vertebral, and hip fracture risk.
Administration: Oral weekly (alendronic acid, risedronate) or monthly (ibandronate); IV infusion annually (zoledronic acid / Aclasta). Oral forms must be taken on an empty stomach with a full glass of water, remaining upright for 30 minutes afterwards to minimise GI side effects.
Indicated for: First-line treatment for most patients with osteoporosis. Men and post-menopausal women with a T-score at or below −2.5, or with one or more fragility fractures.
Clinical note: Bisphosphonate treatment holidays (typically after 3–5 years of oral therapy or 3 years of IV therapy) are recommended in lower-risk patients to reduce the very small risk of atypical femoral fracture. Your consultant will advise on the appropriate duration and timing of any treatment break.
Denosumab
UK brand name: Prolia® (osteoporosis); Xgeva® (oncology use — different indication)
Class: Antiresorptive (RANK ligand inhibitor)
How it works: A fully human monoclonal antibody that binds RANKL and prevents osteoclast formation, function, and survival. Produces bone density gains comparable to or exceeding bisphosphonates and reduces fracture risk at spine and hip.
Administration: Subcutaneous injection 60mg every 6 months, administered by a healthcare professional.
Indicated for: Post-menopausal women with osteoporosis; men with osteoporosis or bone loss associated with androgen deprivation therapy for prostate cancer; patients intolerant of or with contraindications to bisphosphonates.
Clinical note: Unlike bisphosphonates, denosumab’s effect on bone resorption reverses rapidly after stopping treatment. Rebound bone loss and multiple vertebral fractures have been reported after discontinuation. Sequential antiresorptive therapy must be planned with your consultant before commencing denosumab. Never stop denosumab without clinical guidance.
Raloxifene
UK brand name: Evista®
Class: Antiresorptive (Selective Oestrogen Receptor Modulator — SERM)
How it works: Mimics oestrogen’s protective effects on bone in post-menopausal women, inhibiting bone resorption without stimulating breast or uterine tissue. Reduces vertebral fracture risk by approximately 30–50% in post-menopausal women with osteoporosis.
Administration: Oral tablet, once daily.
Indicated for: Post-menopausal women with spinal osteoporosis or osteopenia, particularly those also at elevated breast cancer risk (raloxifene carries a breast cancer risk reduction indication). Not effective for non-vertebral or hip fractures.
Clinical note: Increases the risk of venous thromboembolism (DVT/PE) and should not be used in women with a history of blood clots. Hot flushes may worsen. Not appropriate if mobility is severely limited.
Hormone Replacement Therapy (HRT)
UK brand name: Various preparations — estradiol with progestogen (e.g. Evorel, Femoston, Utrogestan)
Class: Antiresorptive (oestrogen-mediated)
How it works: Oestrogen maintains bone density by inhibiting osteoclast activity. When commenced at or near menopause, HRT prevents the accelerated bone loss associated with oestrogen decline and reduces fracture risk in post-menopausal women.
Administration: Transdermal patches, gel, or nasal spray (oestrogen component); oral or local progestogen for women with a uterus. Various regimens and preparations available.
Indicated for: Post-menopausal women with osteopenia or osteoporosis, particularly those with concurrent menopausal symptoms. Most effective when started early in the post-menopausal period. May be used alongside other osteoporosis treatments.
Clinical note: Individual benefit-risk assessment is essential — the effect on breast cancer risk varies by preparation, duration, and individual factors. Current evidence supports that risks are generally low for most women in the early post-menopausal period, but this should be reviewed with your consultant.
Zoledronic Acid (Zoledronate)
UK brand name: Aclasta® (osteoporosis); Zometa® (oncology use — different indication and dose)
Class: Antiresorptive (bisphosphonate — IV)
How it works: The most potent bisphosphonate, administered as an annual intravenous infusion. Reduces vertebral fracture risk by approximately 70%, non-vertebral fracture risk by 25%, and hip fracture risk by 41% (HORIZON trial).
Administration: IV infusion once annually, administered over at least 15 minutes in a clinical setting. Calcium and Vitamin D supplementation required during treatment.
Indicated for: Patients unable to tolerate or adhere to oral bisphosphonate regimens; following hip fracture; post-menopausal osteoporosis; male osteoporosis; glucocorticoid-induced osteoporosis.
Clinical note: An acute-phase response (flu-like symptoms, fever, myalgia) may occur within 1–3 days of the first infusion, less commonly with subsequent infusions. Adequate hydration before and after infusion is important. Renal function must be checked before each infusion. For further information, see the Royal Osteoporosis Society guidance.
Anabolic Agents
Anabolic drugs stimulate new bone formation by activating osteoblasts — the cells that build bone. They can achieve meaningful increases in bone mineral density and are particularly appropriate for patients with severe osteoporosis, very low T-scores, multiple fractures, or inadequate response to antiresorptive therapy. Anabolic therapy is typically followed by antiresorptive treatment to consolidate the bone density gains achieved.
Teriparatide
UK brand name: Forsteo®
Class: Anabolic (PTH analogue)
How it works: A synthetic fragment comprising the first 34 amino acids of parathyroid hormone. When administered by daily injection, the intermittent PTH receptor stimulation shifts the remodelling balance strongly toward bone formation — producing substantial increases in bone density, particularly in the spine. See the schematic above for the biological basis of the anabolic vs catabolic PTH effect.
Administration: Daily subcutaneous self-injection for a maximum of 24 months (lifetime course — cannot be repeated). Treatment is followed by an antiresorptive agent to consolidate gains.
Indicated for: Patients with severe osteoporosis (T-score below −3.0), multiple vertebral fractures, very high fracture risk, or inadequate response to antiresorptive therapy. Requires special clinical criteria in England for NHS prescribing; available without restriction via private prescription.
Clinical note: Hypercalcaemia and hypercalciuria may occur — calcium intake should be monitored during treatment. Not suitable for patients with a history of bone cancer, radiation therapy to bone, Paget’s disease, or hypercalcaemia.
Romosozumab
UK brand name: Evenity®
Class: Anabolic and antiresorptive (sclerostin inhibitor)
How it works: A monoclonal antibody that inhibits sclerostin, a protein that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation (anabolic) and reduces bone resorption (antiresorptive) — the only licensed osteoporosis treatment with this dual mechanism. Produces rapid, large BMD gains at both spine and hip.
Administration: Subcutaneous injection 210mg (two 105mg injections) once monthly for 12 months, administered by a healthcare professional. Followed by antiresorptive therapy.
Indicated for: Post-menopausal women at very high risk of fracture, particularly those with severe osteoporosis or high-risk vertebral fracture history. Not appropriate for patients with a history of myocardial infarction or stroke within the preceding year.
Clinical note: Cardiovascular risk must be assessed before commencing: romosozumab is contraindicated in patients with recent myocardial infarction or stroke. Calcium and Vitamin D supplementation required during treatment. For further information, see the Royal Osteoporosis Society guidance.
Supplementary Treatments
The following are used alongside pharmacological bone treatments rather than as primary therapies. Adequate calcium and Vitamin D are a prerequisite for all pharmacological osteoporosis treatment — their absence significantly reduces treatment efficacy.
Calcium and Vitamin D
UK brand name: Various: Calcichew D3, Adcal-D3, Calfovit D3; standalone Vitamin D: Fultium-D3, Invita D3
Class: Supplementary (essential micronutrients)
How it works: Calcium is the primary mineral constituent of bone. Vitamin D is essential for intestinal calcium absorption and for the direct action of calcium on bone mineralisation. Together, they are required for the efficacy of all pharmacological osteoporosis treatments.
Administration: Oral supplementation: combined calcium/Vitamin D tablets typically taken once or twice daily with meals. Standalone Vitamin D prescribed where calcium intake from diet is adequate. Doses are individualised following blood testing.
Indicated for: Patients with dietary calcium deficiency, confirmed Vitamin D deficiency, or those on pharmacological osteoporosis treatment (where supplementation is required). Blood levels should be checked before prescribing and monitored during treatment.
Clinical note: Calcium supplements should not be used without confirming dietary deficiency — excess calcium intake has been associated with cardiovascular risk in some studies. Vitamin D toxicity is possible with very high supplementation doses. Both should be prescribed or recommended with clinical oversight.
A Note on Sequential Treatment
Osteoporosis management is rarely a single drug for life. For many patients — particularly those with severe bone loss or high fracture risk — the most effective strategy involves a planned sequence of treatments.
A typical anabolic-first approach begins with 12–24 months of an anabolic agent (teriparatide or romosozumab) to stimulate new bone formation and achieve substantial BMD gains, followed immediately by antiresorptive therapy (usually a bisphosphonate or denosumab) to consolidate and maintain those gains. Without the antiresorptive follow-on, a significant proportion of the BMD gained during anabolic therapy is lost within 12–18 months.
For patients on denosumab specifically, the transition off treatment requires particular care: stopping denosumab without a planned antiresorptive follow-on has been associated with rapid rebound bone loss and, in some cases, multiple vertebral fractures. Your consultant will plan this transition carefully.
The specific sequence, duration, and choice of agents is individualised to the patient’s clinical profile, treatment history, response to monitoring, and preferences. No two treatment plans at LOC are identical.
Which Treatment Is Right for You?
The right pharmacological treatment for osteoporosis depends on your bone density, fracture history, risk profile, co-morbidities, and personal circumstances. A consultant-led assessment at the London Osteoporosis Clinic will provide a complete clinical picture and a personalised treatment recommendation. No GP referral required.
+44 (0)20 7193 7867 | Mon–Fri, 9am–5pm | HCA The Shard, London
